DCVMN Meeting

Innovation in Financing & Technology

October 21, 2022
U.S. International Development Finance Corporation (DFC) is the U.S. Government's development finance institution. DFC partners with the private sector to finance solutions to the most critical challenges facing the developing world today.

Who We Are

What We Offer

Debt
Direct loans and guaranties of up to $1 billion for tenors as long as 25 years, with specific programs targeting small and medium U.S. businesses

Equity
DFC direct equity investments can provide critical support to companies committed to creating developmental impact

Political Risk Insurance
Coverage of up to $1 billion against losses due to currency inconvertibility, government interference, and political violence including terrorism. DFC also offers reinsurance to increase underwriting capacity

Investment Funds
Support for emerging markets private equity funds to help address the shortfall of investment capital

Feasibility Studies
Support for the analysis of a potential DFC project

Technical Assistance
Support to increase the developmental impact or commercial sustainability of existing DFC projects or develop potential DFC projects
Where We Work

$37+ billion in total active commitments across the world
Health Investments

In the **two years** since DFC launched the **Global Health and Prosperity Initiative (HAPI)** in May 2020, the agency has committed nearly **$2 billion to 25 global health projects across regions**
Investment Priorities

DFC has three key health sub-sector priority areas:

Health Services and Infrastructure
- Hospitals
- Health clinics
- Specialty care (e.g., chronic kidney care, eye care)
- Pharmacies
- Diagnostic centers

Health Commodity Manufacturing and Supply Chain
- Vaccines, diagnostics, therapeutics, and ancillary supplies production
- Delivery & logistics

Digital Health and Health Information
- Provider or patient digital health applications
- Electronic health records and other data systems
Vaccine Access and Capacity

DFC has made $1.55b in vaccine related investments

- $1b for liquidity to purchase 160m doses of COVID-19 vaccines and ancillary supplies for COVAX AMC countries
- $383m PRI has shipped nearly 30m doses to date of COVID-19 vaccines for 9 self-financed countries
- $118m working capital loan to build manufacturing capacity of 450m doses annually of COVID-19 or other routine vaccines by 2022
- $50m loan to build manufacturing capacity of 1b doses annually of COVID-19 or other routine vaccines by the end of 2022
- $3.3m TA to potentially build manufacturing capacity of 300m doses annually of COVID-19 or other routine vaccines by 2023 or later
- $200k TA to potentially build manufacturing capacity of 500m doses annually of COVID-19 or other routine vaccines by 2023 or later
Example: Gavi, the Vaccine Alliance

A $1b **direct loan** to Gavi, the Vaccine Alliance, to enable procurement of up to 160 million doses of the COVID-19 vaccine and other ancillary supplies to 84 AMC countries in the COVAX facility. DFC also provided **$383m in PRI** to Gavi to enable immediate shipment of 30 million doses of the COVID-19 vaccine to 9 self-financing countries.
Example: Institute Pasteur de Dakar (IPD)

A $3.3m technical assistance grant to IPD for initial project development for a new flexible vaccine manufacturing facility in Senegal to produce Covid-19 and other vaccines with annual capacity of 300 million doses. IPD has strategic partnerships with BioNTech, CEPI, and MedInstill. DFC is co-investing with other DFI s and coordinating closely across USG.
Challenges & Opportunities

Regulatory
- Quality assurance
- Regulatory approval

Procurement
- Demand
- Competition
- Price premiums
- Offtake agreements

Delivery
- Cold storage, logistics, and supply chain
- Ancillary supplies
- Talent and skillset
- Training

Opportunity to work with USG, global, regional, and local stakeholders (e.g., USAID, GAVI, CEPI, Africa CDC, PAVM etc.) to strengthen the ecosystem for regional health commodity manufacturing